Council Directive 2009/156/EC of 30 November 2009 on animal health conditions governing the movement and importation from third countries of equidae (Codified version) (Text with EEA relevance)
Modified by
- Council Directive 2013/20/EUof 13 May 2013adapting certain directives in the field of food safety, veterinary and phytosanitary policy, by reason of the accession of the Republic of Croatia, 32013L0020, June 10, 2013
- Commission Implementing Decision (EU) 2016/1840of 14 October 2016amending Annex IV to Council Directive 2009/156/EC as regards methods for African horse sickness diagnosis(notified under document C(2016) 6509)(Text with EEA relevance), 32016D1840, October 18, 2016
(a) "holding" means an agricultural or training establishment, a stable or, generally speaking, any premises or facilities in which equidae are habitually kept or bred, for whatever use; (b) "equidae" means wild or domesticated animals of the equine (including zebras) or asinine species or the offspring of crossings of those species; (c) "registered equidae" means any equidae registered as defined in Council Directive 90/427/EEC of 26 June 1990 on the zootechnical and genealogical conditions governing intra-Community trade in equidaeOJ L 224, 18.8.1990, p. 55 .(i) the breeding authority or any other competent authority of the country where the animal originated which manages the studbook or register for that breed of animal; or (ii) any international association or organisation which manages horses for competition or racing;
(d) "equidae for slaughter" means equidae intended to be transported either directly or after transit through an approved marshalling centre, referred to in Article 7, to the slaughterhouse for slaughter; (e) "equidae for breeding and production" means equidae other than those mentioned in (c) and (d); (f) "Member State or third country free from African horse sickness" means any Member State or third country in which there has been no clinical, serological (in unvaccinated equidae) or epidemiological evidence of African horse sickness on the territory concerned in the previous two years and in which there have been no vaccinations against the disease during the previous 12 months; (g) "compulsorily notifiable diseases" means the diseases listed in Annex I; (h) "official veterinarian" means the veterinarian designated by the competent central authority of a Member State or of a third country; (i) "temporary admission" means the status of registered equidae originating in a third country and admitted into Community territory for a period of less than 90 days to be fixed in accordance with the procedure referred to in Article 21(2), depending on the health situation in the country of origin.
are being ridden or taken, for sporting or recreational purposes, along roads situated near internal borders of the Community, are taking part in cultural or similar events or in activities organised by authorised local bodies situated near internal borders of the Community, are intended solely for temporary pasturing or work near internal borders of the Community,
(a) in the case of registered equidae, by means of an identification document, as provided for in Directive 90/427/EEC, which must certify in particular that paragraphs 5 and 6 of this Article and Article 5 of this Directive have been complied with. The official veterinarian must suspend the validity of the identification document for the period of the prohibitions provided for in paragraph 5 of this Article or in Article 5 of this Directive. The identification document must, following the slaughter of the registered horse, be returned to the authority which issued it. The procedure for the implementation of this point shall be adopted in accordance with the procedure referred to in Article 21(2); (b) for equidae for breeding and production, by the method established in accordance with the procedure referred to in Article 21(2).
(a) if all the animals of species susceptible to the disease located on the holding have not been slaughtered, the period of prohibition concerning the holding of origin must be at least: (i) six months in the case of equidae suspected of having contracted dourine, beginning on the date of the last actual or possible contact with a sick animal. However, in the case of a stallion, the prohibition shall apply until the animal is castrated; (ii) six months in the case of glanders or equine encephalomyelitis, beginning on the day on which the equidae suffering from the disease in question are slaughtered; (iii) in the case of infectious anaemia, until the date on which, the infected animals having been slaughtered, the remaining animals have shown a negative reaction to two Coggins tests carried out three months apart; (iv) six months from the last recorded case, in the case of vesicular stomatitis; (v) one month from the last recorded case, in the case of rabies; (vi) 15 days from the last recorded case, in the case of anthrax;
(b) if all the animals of species susceptible to the disease located on the holding have been slaughtered and the premises disinfected, the period of prohibition shall be 30 days, beginning on the day on which the animals were destroyed and the premises disinfected, except in the case of anthrax, where the period of prohibition is 15 days.
(a) the distribution of the disease on its territory; (b) the reasons for the programme, taking into consideration the significance of the disease and its cost/benefit advantages; (c) the geographical area in which the programme will be implemented; (d) the status categories to be applied to establishments, the standards which must be attained for each species and the test procedures to be used; (e) the programme monitoring procedures; (f) the action to be taken if, for any reason, a holding loses its status; (g) the measures to be taken if the results of the tests carried out in accordance with the provisions of the programme are positive; (h) the non-discriminatory nature of trade in the territory of the Member State concerned with respect to intra-Community trade.
(a) clinical, serological (in unvaccinated animals) and/or epidemiological evidence has revealed the presence of African horse sickness in the past two years; or (b) vaccination against African horse sickness has been carried out in the past 12 months.
(a) a protection zone with a radius of at least 100 km around any centre of infection; (b) a surveillance zone of at least 50 km extending beyond the protection zone, in which no vaccination has been carried out in the last 12 months.
(a) they must be dispatched only during certain periods of the year, having regard to the activity of vector insects, to be determined in accordance with the procedure referred to in Article 21(3); (b) they must show no clinical symptom of African horse sickness on the day of the inspection referred to in Article 4(1); (c) they must have undergone a test for African horse sickness as described in Annex IV, on two occasions, with an interval of between 21 and 30 days between the two tests, the second of which must have been carried out during the 10 days prior to dispatch either: (i) with negative results, if they have not been vaccinated against African horse sickness; or (ii) without having recorded an increase in the antibody count and without having undergone vaccination during the previous two months, if they have been vaccinated against African horse sickness.
In accordance with the procedure referred to in Article 21(2), and following the opinion of the European Food Safety Authority, other monitoring methods may be recognised; (d) they must have been kept in a quarantine station for a minimum period of 40 days prior to dispatch; (e) they must have been protected from vector insects during the period of quarantine and during transportation from the quarantine station to the place of dispatch.
(a) registered equidae which leave their holdings are accompanied by the identification document laid down in Article 4(4)(a) together, if they are intended for intra-Community trade, with the health attestation provided for in Annex II; (b) equidae for breeding, production and slaughter are, during their transportation, accompanied by a health certificate complying with Annex III.
(a) the health status of the equidae, other domestic animals and wildlife in the third country, with particular regard to exotic animal diseases and any aspects of the general health and the environmental situation in the third country which may pose a risk to the health and environmental status of the Community; (b) the legislation of the third country in relation to animal health and welfare; (c) the organisation of the competent veterinary authority and its inspection services, the powers of those services, the supervision to which they are subject, and the means at their disposal, including staff and laboratory capacity, to apply national legislation effectively; (d) the assurances which the competent veterinary authority of the third country can give regarding compliance or equivalence with the relevant animal health conditions applicable in the Community; (e) whether the third country is a member of the World Organisation for Animal Health (OIE) and the regularity and rapidity of the information supplied by the third country relating to the existence of infectious or contagious diseases of equidae in its territory, in particular those diseases listed by the OIE and in Annex I to this Directive; (f) the guarantees given by the third country to directly inform the Commission and the Member States: (i) within 24 hours, of the confirmation of the occurrence of infectious diseases of equidae listed in Annex I and of any change in the vaccination policy concerning such diseases; (ii) within an appropriate period, of any proposed changes in the national sanitary rules concerning equidae, in particular regarding the importation of equidae; (iii) at regular intervals, of the animal health status of its territory concerning equidae;
(g) any experience of previous imports of live equidae from the third country and the results of any import controls carried out; (h) the results of Community inspections and/or audits carried out in the third country, in particular the results of the assessment of the competent authorities or, where the Commission so requests, the report submitted by the competent authorities on the inspections which they have carried out; (i) the rules on the prevention and control of infectious or contagious animal diseases in force in the third country and their implementation, including rules on importation of equidae from other third countries.
(a) are free from African horse sickness; (b) have been free for two years from Venezuelan equine encephalomyelitis (VEE); (c) have been free for six months from dourine and glanders.
(a) that the provisions of paragraph 1 of this Article shall apply to only part of the territory of a third country. In the event that the African horse sickness requirements apply on a regional basis, at the very least the measures laid down in Article 5(2) and (5) must be complied with; (b) to require additional guarantees for diseases alien to the Community.
(a) comply with the animal health requirements adopted, with reference to the species in question, the categories of equidae, in accordance with the procedure referred to in Article 21(2) for importation of equidae from that country. The reference basis for fixing those animal health requirements shall be the standards laid down in Articles 4 and 5; and (b) in the case of a third country not free of vesicular stomatitis or viral arteritis for at least six months, the equidae must meet the following requirements: (i) they must come from a holding which has been free of vesicular stomatitis for at least six months and they must have reacted negatively to a serological test prior to dispatch; (ii) in the case of viral arteritis, male equidae must, notwithstanding Article 19(b), have reacted negatively to a serological test or to a virus isolation test or to any other test recognised in accordance with the procedure referred to in Article 21(2) which would guarantee freedom from the virus. In accordance with the procedure referred to in Article 21(2), and following the opinion of the European Food Safety Authority, the categories of male equidae to which this requirement shall apply may be defined.
(a) be issued on the day of loading of the animals for dispatch to the Member State of destination or, in the case of registered horses, on the last working day before embarkation; (b) be drawn up in at least one of the official languages of the Member State of destination and one of those of the Member State in which the import inspection is carried out; (c) accompany the animals in the original; (d) attest that the animals satisfy the requirements of this Directive and those laid down pursuant to this Directive with regard to importation from third countries; (e) consist of a single sheet; (f) be made out for a single consignee or, in the case of animals for slaughter, for a consignment, provided the animals are properly marked and identified. Member States shall inform the Commission if they make use of this option.
(a) it may be decided that importation from a third country or part of a third country is to be confined to particular species or categories of equidae; (b) notwithstanding Article 15, the special conditions for the temporary entry into Community territory of registered equidae or equidae intended for special uses or their re-entry into Community territory after being temporarily exported, shall be established; (c) the conditions for converting temporary entry into permanent entry shall be determined; (d) a Community reference laboratory for one or more of the diseases of equidae listed in Annex I may be designated and the functions, tasks and procedures regarding collaboration with laboratories responsible for diagnosing infectious diseases of equidae in the Member States shall be provided for.
Dourine Glanders Equine encephalomyelitis (of all types, including VEE) Infectious anaemia Rabies Anthrax African horse sickness Vesicular stomatitis
(a) it has been examined today and shows no clinical sign of disease; (b) it is not intended for slaughter under a national programme of contagious or infectious disease eradication; (c) it does not come from the territory or part of the territory of a Member State which is the subject of restrictions for reasons of African horse sickness, or it comes from the territory or part of the territory of a Member State which was subject to prohibition for animal health reasons and has undergone, with satisfactory results, the tests provided for in Article 5(5) of Directive 2009/156/EC in the quarantine station of … between …and… Delete whichever does not apply. it is not vaccinated against African horse sickness, or, it was vaccinated against African horse sickness on … Delete whichever does not apply. The vaccination date must be entered in the passport.
(d) it has not come from a holding which was subject to prohibition for animal health reasons nor had contact with equidae from a holding which was subject to prohibition for animal health reasons: during six months in the case of equidae suspected of having contracted dourine, beginning on the date of the last actual or possible contact with a sick animal. However, in the case of a stallion, the prohibition shall apply until the animal is castrated, during six months in the case of glanders or equine encephalomyelitis, beginning on the day on which the equidae suffering from the disease in question are slaughtered, in the case of infectious anaemia, until the date on which, the infected animals having been slaughtered, the remaining animals have shown a negative reaction to two Coggins tests carried out three months apart, during six months from the last case, in the case of vesicular stomatitis, during one month from the last case, in the case of rabies, during 15 days from the last case, in the case of anthrax, if all the animals of species susceptible to the diseases located on the holding have been slaughtered and the premises disinfected during 30 days, beginning on the day on which the animals were destroyed and the premises disinfected, except in the case of anthrax, where the period of prohibition is 15 days;
(e) to the best of my knowledge, it has not been in contact with equidae suffering from an infectious or contagious disease in the 15 days prior to this declaration; (f) at the time of the inspection it was fit to be transported on the intended journey in accordance with the provisions of Regulation (EC) No 1/2005 This statement does not exempt transporters from their obligations in accordance with Community provisions in force in particular regarding the fitness of animals to be transported. Name in block capitals and capacity. Date Place Stamp and signature of the official veterinarian
Phenol-chloroform extraction of nucleic acids; Adsorption of nucleic acids to filter system; Adsorption of nucleic acids to magnetic beads system.
1.1. 1 g of tissue sample is homogenised in 1 ml of denaturing solution (4 M guanidium thiocyanate, 25 mM sodium citrate, 0,1 M 2-mercaptoethanol, 0,5 % sarcosyl). 1.2. After centrifugation, 1 μg of yeast RNA, 0,1 ml of 2 M sodium acetate pH 4, 1 ml of phenol and 0,2 ml of chloroform/isoamyl alcohol mixture (49/1) are added to the supernatant. 1.3. The suspension is vigorously shaken and cooled on ice for 15 minutes. 1.4. After centrifugation, the RNA present in the aqueous phase is phenol extracted, ethanol precipitated and resuspended in sterile water.
2.1.1. Primer stock concentration is diluted to a working concentration of 8 μM ("primer working stock 8 μM") whereas probe is diluted to a working concentration of 50 μM ("probe working stock 50 μM"). A test plate layout should be designed and loaded into the real time PCR machine software. Using the layout as a guide, 2,5 μl of each primer working stock 8 μM is added to each well that will contain RNA samples, positive and/or negative controls (final concentration of the primer will be 1 μM in the 20 μl RT-PCR mix). The plate is held on ice. 2.1.2. 2 μl of isolated RNA (test samples and positive control), or 2 μl of RNAse-free water in negative reaction controls, is mixed with forward and reverse primers. This mixture is denatured by heating at 95 °C for 5 minutes, followed by rapid cooling on ice for at least 5 minutes. 2.1.3. An appropriate volume of real time one-step RT-PCR master mix for the number of samples to be tested is prepared following manufacturer's instructions. 0,1 μl of probe working stock 50 μM is added to each well containing RNA samples (final concentration of the probe will be 0,25 μM in each well containing RNA samples). 13 μl of real time one-step RT-PCR master mix is distributed in each well on the PCR plate containing the denatured primers and RNA. 2.1.4. The plate is placed in a real time thermal cycler programmed for reverse transcription and cDNA amplification/fluorescence detection. Amplification conditions consist of a first reverse-transcription step at 48 °C for 25 minutes, followed by 10 minutes at 95 °C ("hot start") and 40 cycles of 15 seconds at 95 °C, 35 seconds at 55 °C and 30 seconds at 72 °C (or 40 cycles at 97 °C for 2 seconds and 55 °C for 30 seconds if reagents and thermocycler allowing fast reactions are used). Fluorescence data are acquired at the end of the 55 °C step. 2.1.5. The assay is considered not valid if atypical amplification curves are obtained, and must be repeated. Samples are considered positives, if the Ct value (cycle number at which the fluorescence generated within a reaction crosses the fluorescence threshold) is lower than or equal to the defined Ct threshold (35) within 40 PCR cycles (Ct ≤ 35). Samples are considered inconclusive, if the Ct value is higher than the defined Ct threshold (35) within 40 PCR cycles (Ct > 35). Samples are considered negative, if a horizontal amplification curve is obtained which does not cross the threshold line within 40 PCR cycles.
2.2.1. Primer and probe mix stock solutions are made up in a 25× concentration at 5 μΜ for the forward and reverse primers and 3 μΜ for the probe. A test plate layout should be designed and loaded into the real-time PCR machine software. Using the layout as a guide, 5 μl of RNA samples, including test samples and positive and negative controls, are added to appropriate wells of the plate following the layout. 2.2.2. The RNA is denatured by heating at 95 °C for 5 minutes, followed by rapid cooling on ice for at least 3 minutes. 2.2.3. An appropriate volume of real-time one-step RT-PCR master mix for the number of samples to be tested is prepared, following the manufacturer's instructions. 1 μl of 25× primer probe mix stock solution (from point 2.2.1 above) is included in the master mix to give a final concentration in each well of 200 nM for each primer and 120 nM of the probe. 20 μl of the master mix is distributed in each well on the PCR plate containing the denatured RNA. 2.2.4. The plate is placed in a real-time thermal cycler programmed for reverse transcription and cDNA amplification/fluorescence detection as suggested by the manufacturers. Amplification conditions consist of, for example, a first reverse-transcription step at 48 °C for 10 minutes, followed by 10 minutes at 95 °C and 40 cycles of 15 seconds at 95 °C and 45 seconds at 60 °C. 2.2.5. Samples are considered positives, if the normalised fluorescence for the AHSV RT-PCR assay exceeds a 0,1 threshold within 36 PCR cycles in all replicates of a sample. Samples are considered inconclusive, if the normalised fluorescence for the AHSV RT-PCR assay exceeds a 0,1 threshold between 36 and 40 PCR cycles in any replicate of a sample. Samples are considered negative, if the normalised fluorescence for the AHSV RT-PCR assay did not exceed a 0,1 threshold within 40 PCR cycles in all replicates of a sample and if the normalised fluorescence for the proprietary synthetic external control assay exceeded a 0,1 threshold within 33 PCR cycles.
| only Article 15(3) | |
| only as regards the reference to Directive 90/426/EEC in Article 26(2) | |
| only Article 1 | |
| only as regards the reference to Directive 90/426/EEC in Article 1(1), and Annex I, pt. 2 | |
| only Annex III, point 10 | |
| only Article 15 | |
| only Annex, point I.2. | |
| only Article 7 |
| Directive | Time-limit for transposition |
|---|---|
| 90/426/EEC | |
| 90/425/EEC | |
| 91/496/EEC | |
| 92/36/EEC | |
| 2004/68/EC | |
| 2006/104/EC | |
| 2008/73/EC |
| Directive 90/426/EEC | This Directive |
|---|---|
| Article 1 | Article 1 |
| Article 2(a) and (b) | Article 2(a) and (b) |
| Article 2(c) | Article 2(c)(i) and (ii) |
| Article 2(d) to (i) | Article 2(d) to (i) |
| Article 3 | Article 3 |
| Article 4(1), (2) and (3) | Article 4(1), (2) and (3) |
| Article 4(4)(i) and (ii) | Article 4(4)(a) and (b) |
| Article 4(5)(a), first to sixth indents | Article 4(5)(a)(i) to (vi) |
| Article 4(5)(b) | Article 4(5)(b) |
| Article 4(6), first subparagraph, first to eighth indents | Article 4(6), first subparagraph, (a) to (h) |
| Article 4(6), second and third subparagraphs | Article 4(6), second and third subparagraphs |
| Article 5(1) | Article 5(1) |
| Article 5(2)(a) | Article 5(2), first subparagraph, (a) and (b) |
| Article 5(2)(b) | Article 5(2), second subparagraph, (a) and (b) |
| Article 5(2)(c) | Article 5(3) |
| Article 5(2)(d) | Article 5(4) |
| Article 5(3)(a) and (b) | Article 5(5)(a) and (b) |
| Article 5(3)(c), first and second indents | Article 5(5)(c), first subparagraph, (i) and (ii) |
| Article 5(3)(c), second indent, last sentence | Article 5(5)(c), second subparagraph |
| Article 5(3)(d) and (e) | Article 5(5)(d) and (e) |
| Article 6 | Article 6 |
| Article 7 | Article 7 |
| Article 8(1), first subparagraph, first and second indents | Article 8(1)(a) and (b) |
| Article 8(1), second subparagraph | Article 8(2) |
| Article 8(2) | Article 8(3) |
| Article 9 | Article 9 |
| Article 10 | Article 10 |
| Article 11(1) | Article 11 |
| Article 11(2) | — |
| Article 12 | Article 12 |
| Article 13 | Article 13 |
| Article 14 | Article 14 |
| Article 15 | Article 15 |
| Article 16(1)(a) to (f) | Article 16(1)(a) to (f) |
| Article 16(1), final sentence | — |
| Article 16(2) | Article 16(2) |
| Article 17 | Article 18 |
| Article 18 | Article 17 |
| Article 19(i) to (iv) | Article 19(a) to (d) |
| Article 22 | — |
| Article 23 | Article 20 |
| Article 24(1) and (2) | Article 21(1) and (2) |
| Article 24(3) | — |
| Article 25(1) and (2) | Article 21(1) and (3) |
| Article 26 | — |
| Article 27 | — |
| — | Article 22 |
| — | Article 23 |
| Article 28 | Article 24 |
| Annex A | Annex I |
| Annex B | Annex II |
| Annex C | Annex III |
| Annex D | Annex IV |
| — | Annex V |
| — | Annex VI |